Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Thea Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution
Details : Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Product Name : Tafluprost-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
November 18, 2022
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Thea Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable